Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $104.1 million.

  • Agios Pharmaceuticals' Total Liabilities fell 1483.28% to $104.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.1 million, marking a year-over-year decrease of 1483.28%. This contributed to the annual value of $104.1 million for FY2025, which is 1483.28% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Total Liabilities stood at $104.1 million for Q4 2025, which was down 1483.28% from $101.4 million recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year Total Liabilities high stood at $191.8 million for Q1 2021, and its period low was $89.0 million during Q1 2025.
  • Over the past 5 years, Agios Pharmaceuticals' median Total Liabilities value was $124.2 million (recorded in 2023), while the average stood at $127.3 million.
  • In the last 5 years, Agios Pharmaceuticals' Total Liabilities plummeted by 6785.53% in 2021 and then surged by 3712.74% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Total Liabilities stood at $145.8 million in 2021, then decreased by 5.39% to $137.9 million in 2022, then dropped by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024, then decreased by 14.83% to $104.1 million in 2025.
  • Its Total Liabilities stands at $104.1 million for Q4 2025, versus $101.4 million for Q3 2025 and $101.7 million for Q2 2025.